Dr. Jeffrey M. Brown is an experienced biotech leader with expertise in preclinical and IND-enabling research. Jeffrey has worked across multiple therapeutic areas including CNS, non-CNS and genetically-defined diseases. This includes experience in several therapeutic modalities including antisense oligonucleotides, gene therapy, siRNA, and small molecules.

Dr. Brown has led more than 20 preclinical programs, successfully advancing a number of these into clinical development. Throughout his career, Jeffrey has built several drug discovery platforms focused on small molecules and nucleic acid-based therapeutics across multiple organizations including Bristol-Myers Squibb, Alexion, Voyager Therapeutics, and Wave Life Sciences. Jeffrey received a Ph.D. in Pharmacology and Toxicology from the University of Utah and a MBA from Suffolk University. Following his Ph.D., Jeffrey completed post-doctoral training at Harvard Medical School and Boston University Medical Center. Combining his drug discovery experience with his passion for helping patients affected with rare disease, Jeffrey founded Scientific Foundation LLC, an organization dedicated to helping families, patients, and biotech start-ups navigate the challenges of preclinical drug development.